The present invention relates generally to a heart assist device, system and method and more particularly to a percutaneous gas-line for an implanted medical device such as a left ventricular assist device (LVAD), or counter-pulsation or co-pulsation heart assist device and to a heart assist device incorporating such a gas-line.
International PCT patent application no. PCT/US00/22992 (WO 01/13974) discloses a gas-driven device heart assist device, that requires a percutaneous positioned gas-line.
U.S. Pat. No. 6,132,363 discloses a percutaneous access device (PAD) system, that allows both gas and electrical transmission, that utilises an intermediary connector piece that has the patient's own fibroblasts cultured onto the hub of the PAD. This has the proposed advantage of reducing infection. However, its disadvantages include its large size, inflexible nature, and that implantation is a two or three staged procedure. Specifically, implantation involves making a large skin biopsy, isolating the fibroblasts from the biopsy and growing the cells, then culturing them onto the device (which is a 10 day process). When the culturing process has been completed, the PAD can be implanted in the abdomen, and then the counterpulsation device implanted.
It is an object of the present invention to provide an improved percutaneous gas-line that, at least in preferred embodiments, requires no antecedent preparation and has a low risk profile for infection, but which allows remedial action to be taken in the event that gas-line infection occurs. It is well known that infection related to percutaneous lines in general is influenced by the diameter, flexibility and nature of the material. As such, a smaller, more flexible and soft (particularly Silicone) material are most advantageous in reducing infection—this is in direct contrast to the PAD as disclosed above.
It is a further object to provide a gas line for a heart assist device which gas line incorporates an ECG lead to provide for monitoring of the heart internally of the patient's body to control the operation of the heart assist device.
Accordingly, in a first aspect, the present invention provides a percutaneous gas-line for a medical device, the gas-line including:
a first gas-line part adapted to be wholly implanted in a patient and having a first end adapted for sealing connection to the medical device and a second end with a connection fitting; and
a second gas-line part adapted to be part-implanted and part-external and having a first (external) end adapted for sealing connection to an external driver and a second (implanted) end adapted for removable sealing connection with the connection fitting on the second end of the first gas-line part.
The second gas-line part is preferably further adapted to be removable, for replacement, in the presence of persistent exit-site infection or damage to the external part.
The medical device is preferably a heart assist device, more preferably a left ventricular assist device (LVAD), or a counter-pulsation or co-pulsation heart assist device.
The first (external) end of the second gas line is preferably removably connected to the external driver.
In preferred embodiments of the invention, an ECG lead adapted to connect a patient's heart with a control system for a heart assist device utilising the gas line according to this invention is incorporated into the first gas line part and/or the second gas line part.
The second gas-line part is preferably constructed to have a minimal outside diameter, more preferably less than 7 mm, and has high flexibility and a resistance to kinking or collapsing. The second gas-line part is preferably made of a soft biocompatible, biostable material, such as silicone 45-65A durometer. This gas-line part may be wire-wound internally to allow thin wall and kink/collapse resistance.
The connection fitting is preferably a Luer-lock or similar gas-tight fitting.
The first and/or second gas-line parts preferably have a fluffy polyester, or similar, collar over about a short section (eg. 20-50 mm) of their implanted length. The collar being adapted to encourage sub-cuateous tissue ingrowth to help reduce any movement of the gas-line in situ—the collar is preferably at least 20 mm from the percutaneous exit site.
In a second aspect, the present invention provides a method of providing heart assistance to a patient using a percutaneous gas-line having a first gas-line part, adapted to be wholly implanted, and a second gas-line part, adapted to be part implanted and part external, connected to the first gas-line part, the method including the steps of:
(1) recognising a persistent exit-site infection;
(2) disconnecting the second gas-line part from the first gas-line part;
(3) removing the second gas-line part from the patient; and
(4) connecting a sterile second gas-line part to the first gas-line part
wherein the fresh second gas-line part is inserted through a fresh exit-site that is remote to the infected exit-site.
It will also be understood by persons skilled in the art that the fresh second gas-line part is inserted through an implant tunnel that is also substantially remote from the existing implant tunnel.
Alternatively, after step (3), the first gas-line part (and the implanted ECG cable, if it is attached to a corresponding interconnect cable associated with the second gas-line part) is sealed and wounds are closed to allow healing to occur (which may include prolonged treatment with antibiotics), at this time the device is non-functional, but can, at a later time, be made functional by re-implanting the second part and sealing attaching it to the first part.
In a third aspect, the present invention provides a gas line for connecting an inflatable heart assist actuator to a driver therefore, the gas line having a first end operatively connected to the inflatable actuator and a second end connectable, directly or indirectly through an extension gas line, to the driver for the heart assist actuator, the gas line having attached to it an ECG lead, the ECG lead having a first end adapted for connection to the heart of a patient and a second end adapted for connection to the driver or a controller for the driver, the attachment between the gas lead and the ECG lead being such that they are adapted to pass through the skin of a patient as a single element.
A preferred embodiment of the invention will now be described, by way of an example only, with reference to the accompanying drawing in which:
The gas-line 10 connects an external gas driver 12 to a left ventricle heart assist device 14, which is positioned around a patient's aorta 16. The heart assist device 14 comprises a balloon (not shown), a bushing (not shown), and a wrap 18 to hold the balloon in position around the aorta 16.
The first part 10a of the gas-line 10 has a first end 10a′ sealingly connected to the bushing and in gas communication with the balloon. The first part 10a of the gas-line 10 also has a second end 1Oa″ with a gas-tight Leur-lock fitting 20 thereon. The first part 10a of the gas-line 10 is made of a polyurethane-polysiloxane block co-polymer similar to that used to form the balloon and bushing.
The second part of 10b of the gas-line 10 is shown positioned percutaneous through an exit site 22. The external/un-implanted portion of the second part 10b has a first end l0b′ that is connected to the external driver 12 with a gas tight but removable fitting. The second gas-line part 10b also has a second end 10b″ connected to the second end 10a″ of the first part 10a at the Luer fitting 20, such that the first gas-line part 10a and the second gas-line part 10b extend from the Luer fitting 20 in a substantially coaxial or straight configuration as shown. The implanted portion of the second part 10b also has about it a polyester collar 24 for anchoring the gas-line subcutaneously approx 20-50 mm from an exit site 22.
The second part 10b can be made of a different material to the first part 10a. It is preferably made of silicone or silicone-polyurethane co-polymer. The second part 10b can also be more flexible than the first part 10a and can be wire-wound.
In the event that the external part of the gas-line 10 is damaged in every-day use, or if a persistent infection develops at the exit site 22, then the second part 10b is able to be exchanged for a fresh/new (sterilised) second part 10b which is brought out of the patient via a new exit-site 22 (see phantom lines). As this can be done without need to replace the whole heart assist device arrangement, the surgery is minimal. More 25 particularly, the surgery only involves a small incision (not shown) over the subcutaneous connection, undoing of the connection of the Luer lock 20, and removal ofthe second part 10b. A new exit-site 22 is then made, and a new second part 10b tunnelled through to the first incision for reconnection of the first 10a and (new) second 10b parts. Ifthe infection has travelled up the original second gas line part 10b then the fresh second gas-line part is 30 inserted through an implant tunnel that is also substantially remote from the existing implant tunnel.
The gas-line 10′ includes a first part (implanted) epicardial ECG lead 26, a sleeve 28 and a second part (percutaneous) ECG lead 30. The lead 26 enters the sleeve 28, which is connected between the first and second parts of the gas line 10a and 10b. The sleeve 28 has an electrical connector therein (not shown) that connects the lead 26 to an extension of the lead 30. The lead parts 26 and 30 therefore advantageously provide direct communication of ECG signals from the patient's heart to the driver 12.
The lead 30 is connected to the driver 12 and is contained within the interior of the gas-line second part 10b. Alternatively, the lead 30 can be glued to the exterior of the gas-line second part 10b. In either case, only a single exit site 22 is required, thereby minimising infection risk and patient discomfort.
It will be appreciated by the persons skilled in the art that numerous variations and/or modifications can be made to the invention as shown in the specific embodiment without departing from the spirit or scope of the invention as broadly defined. For example, the blood displacing devices are described above in relation to extra-aortic counter-pulsation but also suitable for intra aortic counter-pulsation devices, co-pulsation devices, or pneumatic driven LVADs.
Number | Date | Country | Kind |
---|---|---|---|
2003906067 | Oct 2003 | AU | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/AU2004/001485 | 10/28/2004 | WO | 00 | 4/28/2006 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2005/042082 | 5/12/2005 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
0283660 | Reed | Aug 1883 | A |
0929571 | Dubied | Jul 1909 | A |
1576397 | Yanagi | Jul 1925 | A |
1719316 | Appleton | Jul 1929 | A |
3467077 | Cohen | Sep 1969 | A |
3552383 | Krueger et al. | Jan 1971 | A |
3597766 | Buck | Aug 1971 | A |
4014318 | Dockum et al. | Mar 1977 | A |
4051840 | Kantrowitz et al. | Oct 1977 | A |
4176411 | Runge | Dec 1979 | A |
4195623 | Zeff et al. | Apr 1980 | A |
4236482 | Gingerich et al. | Dec 1980 | A |
4256094 | Kapp | Mar 1981 | A |
4277706 | Isaacson | Jul 1981 | A |
4304225 | Freeman | Dec 1981 | A |
4454891 | Dreibelbis et al. | Jun 1984 | A |
4457673 | Conley et al. | Jul 1984 | A |
4459977 | Pizon et al. | Jul 1984 | A |
4515587 | Schiff | May 1985 | A |
4583523 | Kleinke et al. | Apr 1986 | A |
4594731 | Lewkowicz | Jun 1986 | A |
4630597 | Kantrowitz et al. | Dec 1986 | A |
4676482 | Reece et al. | Jun 1987 | A |
4697574 | Karcher et al. | Oct 1987 | A |
4763646 | Lekholm | Aug 1988 | A |
4771765 | Choy et al. | Sep 1988 | A |
4809676 | Freeman | Mar 1989 | A |
4813952 | Khalafalla | Mar 1989 | A |
4822357 | Forster et al. | Apr 1989 | A |
4881939 | Newman | Nov 1989 | A |
4957477 | Lundback | Sep 1990 | A |
4979936 | Stephenson et al. | Dec 1990 | A |
5089017 | Young et al. | Feb 1992 | A |
5197980 | Gorahkov et al. | Mar 1993 | A |
5205810 | Guiraudon et al. | Apr 1993 | A |
5222980 | Gealow | Jun 1993 | A |
5267940 | Moulder | Dec 1993 | A |
5273518 | Lee | Dec 1993 | A |
5290249 | Foster et al. | Mar 1994 | A |
5300111 | Panton et al. | Apr 1994 | A |
5337752 | Reeves | Aug 1994 | A |
5344385 | Buck et al. | Sep 1994 | A |
5360445 | Goldowsky | Nov 1994 | A |
5372573 | Habib | Dec 1994 | A |
5429584 | Chiu | Jul 1995 | A |
5447523 | Schaldach | Sep 1995 | A |
5453076 | Kiyota et al. | Sep 1995 | A |
5511551 | Sano et al. | Apr 1996 | A |
5554177 | Kieval et al. | Sep 1996 | A |
5569156 | Mussivand | Oct 1996 | A |
5593414 | Shipp et al. | Jan 1997 | A |
5607378 | Winston | Mar 1997 | A |
5647380 | Campbell et al. | Jul 1997 | A |
5722930 | Larson, Jr. et al. | Mar 1998 | A |
5792195 | Carlson et al. | Aug 1998 | A |
5814012 | Fleenor et al. | Sep 1998 | A |
5820542 | Dobak, III et al. | Oct 1998 | A |
5827171 | Dobak, III et al. | Oct 1998 | A |
5843170 | Ahn | Dec 1998 | A |
5975140 | Lin | Nov 1999 | A |
5980488 | Heilman et al. | Nov 1999 | A |
6030336 | Franchi | Feb 2000 | A |
6045496 | Pacella et al. | Apr 2000 | A |
6066085 | Heilman et al. | May 2000 | A |
6132363 | Freed et al. | Oct 2000 | A |
6132636 | Singh et al. | Oct 2000 | A |
6210318 | Lederman | Apr 2001 | B1 |
6226843 | Crainich | May 2001 | B1 |
6251061 | Hastings et al. | Jun 2001 | B1 |
6432039 | Wardle | Aug 2002 | B1 |
6471633 | Freed | Oct 2002 | B1 |
6553263 | Meadows et al. | Apr 2003 | B1 |
6572534 | Milbocker et al. | Jun 2003 | B1 |
6585635 | Aldrich | Jul 2003 | B1 |
6616596 | Milbocker | Sep 2003 | B1 |
6626821 | Kung et al. | Sep 2003 | B1 |
6643548 | Mai et al. | Nov 2003 | B1 |
6808483 | Ortiz et al. | Oct 2004 | B1 |
6808484 | Peters et al. | Oct 2004 | B1 |
6984201 | Khaghani et al. | Jan 2006 | B2 |
7169109 | Jansen et al. | Jan 2007 | B2 |
7360558 | Peters et al. | Dec 2007 | B1 |
7347811 | Peters et al. | Mar 2008 | B2 |
7357771 | Peters et al. | Apr 2008 | B2 |
7513864 | Kantrowitz et al. | Apr 2009 | B2 |
7740575 | Peters et al. | Jun 2010 | B2 |
7765003 | Miller et al. | Aug 2010 | B2 |
20030105497 | Zhu et al. | Jun 2003 | A1 |
20040073080 | Peters et al. | Apr 2004 | A1 |
20040097783 | Peters et al. | May 2004 | A1 |
20040097784 | Peters et al. | May 2004 | A1 |
20040147803 | Hegde et al. | Jul 2004 | A1 |
20060052866 | Gilles et al. | Mar 2006 | A1 |
20070093684 | Peters et al. | Apr 2007 | A1 |
20070129796 | Miller | Jun 2007 | A1 |
20070135677 | Miller et al. | Jun 2007 | A1 |
20070167898 | Peters et al. | Jul 2007 | A1 |
20080027270 | Peters et al. | Jan 2008 | A1 |
20080139873 | Peters et al. | Jun 2008 | A1 |
20080167515 | Peters et al. | Jul 2008 | A1 |
Number | Date | Country |
---|---|---|
2003277983 | Jun 2008 | AU |
1541311 | Nov 1966 | DE |
0080348 | May 1988 | EP |
0363203 | Apr 1990 | EP |
0216042 | Mar 1991 | EP |
0601804 | Jun 1994 | EP |
0364799 | May 1995 | EP |
1129736 | Sep 2001 | EP |
2458288 | Jan 1981 | FR |
2645739 | Oct 1990 | FR |
2767874 | Mar 1999 | FR |
2422114 | Apr 2008 | GB |
9-502376 | Mar 1997 | JP |
9-503933 | Apr 1997 | JP |
10-328297 | Dec 1998 | JP |
H11-285529 | Oct 1999 | JP |
2000-510006 | Aug 2000 | JP |
WO 9208500 | May 1992 | WO |
WO 9308874 | May 1993 | WO |
WO 9505122 | Feb 1995 | WO |
WO 9528127 | Oct 1995 | WO |
WO 9740755 | Nov 1997 | WO |
WO 9805289 | Feb 1998 | WO |
WO 9814239 | Apr 1998 | WO |
WO 9851367 | Nov 1998 | WO |
WO 9902213 | Jan 1999 | WO |
WO 9904833 | Feb 1999 | WO |
WO 9945981 | Sep 1999 | WO |
WO 00012168 | Mar 2000 | WO |
WO 00076288 | Dec 2000 | WO |
WO 0113974 | Mar 2001 | WO |
WO 0183001 | Nov 2001 | WO |
WO 02024254 | Mar 2002 | WO |
WO 02024255 | Mar 2002 | WO |
WO 02076305 | Oct 2002 | WO |
WO 03011365 | Feb 2003 | WO |
WO 03028787 | Apr 2003 | WO |
WO 2004045677 | Jun 2004 | WO |
WO 2005041783 | May 2005 | WO |
WO 2005042063 | May 2005 | WO |
WO 2005044338 | May 2005 | WO |
WO 2005110512 | Nov 2005 | WO |
WO 2008053469 | May 2008 | WO |
WO 2008071223 | Jun 2008 | WO |
Number | Date | Country | |
---|---|---|---|
20070021830 A1 | Jan 2007 | US |